Funding opportunities

Below is a list of funding opportunities that may be relevant for thoracic cancer research, including basic scientific research. Please read the funding guidelines to determine if your research proposal is eligible and that you meet other eligibility requirements.

Any TOGA member can apply for TOGA endorsement of their thoracic cancer research proposal, taking advantage of peer- and consumer-review by TOGA working groups in the following areas:

  1. Early non small cell lung cancer
  2. Advanced non small cell lung cancer
  3. Small cell lung cancer/mesothelioma
  4. Supportive and palliative care
  5. Translational research

TOGA endorsement offers the following benefits:

  • Use of TOGA logo or TOGA acknowledgment on all applications, presentations and publications
  • Membership mailouts to assist with recruitment
  • Listing of trial on the TOGA website
  • Updates presented at Scientific Committee or other TOGA meetings (time permitting)

Further information is available in the TOGA Endorsement Policy.

The next deadline for submission of concepts for peer- and consumer review and application for endorsement will be posted on social media and circulated in a members’ newsletter. Send concepts at any time to

If you know of additional funding opportunities that we can list, please contact

Grant NameResearch fundedGrant open dateClose dateMax fundingDurationApplication requirements
WA Cancer Council Cancer Research Project GrantsAboriginal health; rural and remote health; clinical health; and public healthMay 15, 2024Expression of interest: June 26, 2024

Full application (on request) October 8, 2024
$140K1 yearCIA must hold a primary appointment at a Higher Education and/or Medical Research Institute in WA. Early and mid career researchers strongly encouraged as CIs.
More Info
FY24 Lung Cancer Research Program - Patient-Centered Outcomes and Survivorship AwardSupports high-reward studies that span the spectrum of behavioural health science, survivorship, and health outcomes/comparative effectiveness research, including quality of life, symptom and side effect management, resilience, comorbid conditions and examining the physical, psychological, social, and economic effects of lung cancer.March 28, 2024Pre-Application
(Letter of Intent):
July 17, 2024
5:00 p.m. ET

August 7, 2024
11:59 p.m. ET
$650K3 yearsApplications must be submitted via eBRAP
GO6578 – 2023 Innovative Trials National Critical Research Infrastructure Initiative Various opportunities examining:
-feasibility of national adaptive platform trials
-establishment or expansion of a national adaptive trial in an area of unmet need
-Conduct a registry-randomised trial in an area of unmet need
-Evidence of efficiency/cost effectiveness of registry randomised trials or adaptive trial platforms over conventional trial designs
6 February 202410-Jul-2024 5:00 pm (ACT Local Time)Up to $5 million2 yearscomplete the online program application form

GO6361 NHMRC-EU Collaborative Research Grant Scheme 2024Projects involving Australian-based researchers chosen by the EU for funding may be eligible for NHMRC support. NHMRC is considering supporting Australian researchers for Horizon Europe submitted through the two-stage deadline model.12 July 2023
Currently open
16 October 2024 (17:00 ACT time)$1 Million5 yearsApplication form submitted through Sapphire
MRFF - 2024 International Clinical Trial Collaborations Grant OpportunityAustralian involvement in international collaborative investigator-initiated clinical trials research through the establishment and co-ordination of clinical trial site/s in Australia.6 March 2024Min data 31 July 2024 (17:00 ACT time)
Full application due 4 December 2024 (17:00 ACT time)
$3 million5 yearsApplicants are advised to read the Grant Guidelines.

Applications must be submitted using Sapphire, the NHMRC's grant system.